Across TCGA pan-cancer cohorts, LEPROT Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LEPROT data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher LEPROT Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LEPROT expression acts as an unfavorable survival marker.

LUSC and PRAD are the cancer types where LEPROT Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.237	0.660	.021	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: LEPROT tumor-vs-normal RNA expression · all LEPROT data types